Phase 3 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have signed a written consent form to take part in the study
- People who are currently on ongoing dialysis treatment, OR whose kidney function test results (called eGFR) show a reading below 20 on at least two separate occasions at least 3 months apart — with at least one of those readings below 15 — due to chronic kidney disease, within the past 12 months
- People who have been diagnosed with a recurring, ongoing, or permanent irregular heart rhythm known as atrial fibrillation (AF) or atrial flutter (AFL)
- People whose stroke risk score (called CHA2DS2-VASc) is 2 or higher for men, or 3 or higher for women, which indicates a need for blood-thinning medication
- Women who could become pregnant must have a negative pregnancy test at the start of the study and must agree to use contraception throughout the treatment period
Who may not be able to join:
- People whose AF or AFL is caused by a treatable, temporary condition (such as a thyroid problem or inflammation around the heart)
- People who have a certain type of heart valve narrowing (mitral stenosis), whether caused by rheumatic disease at any level, or by other causes if it is moderate to severe
- People who need long-term blood-thinning medication for a reason other than AF or AFL — for example, a mechanical heart valve or a condition called antiphospholipid syndrome
- People who have any reason they cannot safely take blood-thinning medication, including: a heart infection (endocarditis), a known intolerance to the specific study medication (apixaban), a liver disease that affects blood clotting, or who are pregnant or breastfeeding
- People who are currently bleeding actively, or who have had a serious bleeding episode within the past 3 months, or who have a blood disorder that causes bleeding, or who are currently taking two different types of blood-thinning platelet medications at the same time
- People who are planned to have certain surgeries, including: a kidney transplant from a living donor within the next 3 months; a heart valve surgery; or people on a kidney transplant waiting list at a centre where the study medication (apixaban) is not permitted (confirm with trial site)
- People who regularly take certain medications that are known to interact with the study drug apixaban — including specific strong-acting medications that affect how the body processes drugs, or regular use of anti-inflammatory pain medications such as NSAIDs or COX-2 inhibitors
- People whom the study doctor believes should not take part, for any documented reason
Note: Being on a kidney transplant waiting list does not automatically prevent someone from joining, provided the transplant centre's current guidelines allow the use of apixaban. Any changes to waiting list status must be reported to the study team promptly (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marie Evans, Ass Prof, Karolinska University Hospital
Phone: +46760520852
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ischemic stroke or systemic embolism (efficacy); Intracranial bleeding (including hemorrhagic stroke) and fatal bleeding (safety)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.